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Abstract Lung cancer is recognized as a leading cause of
cancer-related death worldwide and its frequency is still
increasing. The prognosis in lung cancer is poor and lim-
ited by the difficulties of diagnosis at early stage of disease,
when it is amenable to surgery treatment. Therefore, the
advance in identification of lung cancer genetic and epi-
genetic markers with diagnostic and/or prognostic values
becomes an important tool for future molecular oncology
and personalized therapy. As in case of other tumors,
aberrant epigenetic landscape has been documented also in
lung cancer, both at early and late stage of carcinogenesis.
Hypermethylation of specific genes, mainly tumor sup-
pressor genes, as well as hypomethylation of oncogenes
and retrotransposons, associated with histopathological
subtypes of lung cancer, has been found. Epigenetic aber-
rations of histone proteins and, especially, the lower global
levels of histone modifications have been associated with
poorer clinical outcome in lung cancer. The recently dis-
covered role of epigenetic modifications of microRNA
expression in tumors has been also proven in lung carci-
nogenesis. The identified epigenetic events in lung cancer
contribute to its specific epigenotype and correlated phe-
notypic features. So far, some of them have been suggested
to be cancer biomarkers for early detection, disease mon-
itoring, prognosis, and risk assessment. As epigenetic
aberrations are reversible, their correction has emerged as a
promising therapeutic target.
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Introduction
Nowadays it is clearly acknowledged, that during neo-
plastic transformation genetic lesions are accompanied by
equally important epigenetic modifications. The altered
methylation pattern of promoter sequence can cause the
same effect as the mutation in coding region of the gene
and may be subject to the same processes of selection as
genetic changes during carcinogenesis [1, 2]. What’s more,
the mutual interaction between the two mechanisms—
genetic and epigenetic—has been confirmed [3–5]. Epi-
genetic modifications may lead to point mutations, as in
case of epigenetically silenced DNA repair genes, and
conversely, genetic mutations can disturb normal methyl-
ation pattern [6, 7]. Additionally, it has been observed that
epigenetic modifications are much more diverse and fre-
quent than DNA mutations [1, 3, 8].
Epigenetic mechanisms, related to inherited changes in
gene expression without alterations in the primary DNA
sequence [8, 9], are essential for normal cellular function-
ing. They play particularly important role in genome activity
regulations, encompassing key biological processes, such as
differentiation and embryonic development, tissue-specific
gene expression regulation or imprinting and X chromo-
some silencing in females. Epigenetic mechanisms com-
prise DNA methylation, histone modifications, nucleosome
positioning, and small, noncoding RNAs (miRNA, siRNA)
regulation. During the last few decades, epigenetic altera-
tions are widely described as essential players in cancer
development and progression [10]. Epigenetic changes have
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been identified as putative cancer biomarkers for early
detection, cancer management and monitoring, as well as
disease prognosis, and risk assessment.
As so far, the best known epigenetic modifications
observed in human tumor cells are aberrant DNA methyl-
ation patterns—the first epigenetic alterations identified in
cancer—and nucleosomal histone modifications. The first
articles on this subject were published in 1980s. The sub-
sequent studies showed that the spatial conformation of
chromatin, associated with nucleosome positioning, also
affects gene expression. Recently, the role of non-coding
RNA (ncRNA) in the epigenetic control has been descri-
bed. Publications regarding this level of epigenetic signa-
ture have appeared during the last 4 years. So, the
molecular mechanisms underlying epigenetic regulatory
processes have been discovered relatively recently, and the
knowledge of this field is still enriched. The most frequent
epigenetic modifications in cancer cell and the involved
mechanisms are summarized in Table 1.
The final result of epigenetic modifications, listed in
Table 1, is the altered structure of chromatin involved in
packaging of the human genome. This process, the so
called chromatin remodeling, is associated with chromatin
conformational changes into functionally active structure
(euchromatin) or inactive condensed form (heterochroma-
tin) [1, 11, 12]. The additional epigenetic level in gene
expression control is carried out by deregulation of non-
coding RNA function and post-transcriptional miRNA
control of 30untranslated regions (30UTR) of target mes-
senger RNAs via transcript destabilization and mRNAs
repression and/or inhibition of translation [13].
Although cancer is traditionally regarded as genetic
disorder, it has been thoroughly documented that epige-
netic changes are very powerful modulators of cellular
phenotype in pathological mechanism of carcinogenesis.
Figure 1 depicts molecular changes—both genetic and
epigenetic—during lung carcinogenesis.
The effect of epigenetic modifications on gene
expression
It is well documented that the presence of methylated cy-
tosines in CpG islands within gene promoter sequence
prevents binding of the transcription machinery or allows
binding of transcription repressors [8, 10, 14]. So, the effect
of DNA methylation is gene silencing related to the inhi-
bition of its transcription. In case of histone modifications,
their activating/inhibiting influence on gene transcription
depends upon the localization of modified amino acid and
specific core histone, the so called ‘‘histone code’’ [15, 16].
Particularly important are the N-terminal modifications of
histones H3 and H4. For example, acetylation of lysine 4 in
histone H3 (H3K4) enables active gene transcription, and its
deacetylation results in gene silencing [15, 17–19].
Regarding methyl group binding to the histones, trimethy-
lation of H3K4 (H3K4me3) is observed in transcriptionally
active chromatin, while trimethylation of lysine 27 in H3
(H3K27me3) has suppressive effect [15, 17, 19, 20].
Both DNA methylation and histone modifications are
enzymatic processes and are reversible. The enzymes par-
ticipating in histone modifications are histone acetyltrans-
ferases (HATs), histone methyltransferases (HMTs), histone
deacetylases (HDACs) and histone demethylases (HDMs)
[8, 17, 19]. DNA methylation is mediated by DNA methyl-
transferases (DNMTs). In human, there are three catalyti-
cally active DNMT forms (DNMT1, DNMT3A, DNMT3B).
DNMT1 is responsible for maintaining the existing pattern
of methylation, while DNMT3A and 3B mediate de novo
methylation [12, 21, 22]. Methylated promoter sequence is
Table 1 The examples of epigenetic modifications and the underlying molecular mechanisms in cancer cell [8, 147]
Epigenetic modification and their molecular mechanisms
DNA methylation
Hypermethylation: covalent binding of methyl groups (-CH3) to cytosines within CpG dinucleotide-rich DNA sequence (CpG islands)
Hypomethylation: separation of methyl groups from normally methylated cytosines in DNA sequence
Histone modifications
Methylation, acetylation, phosphorylation, ubiquitination, glycosylation, ADP-ribosylation, and sumoylation of amino acid residues
(K/Lys/, S/Ser/, T/Thr/, R/Arg/) in core histones
Nucleosome positioning
ATP-dependent chromatin remodeling complexes and nucleosomal remodeling factors (NuRFs) activity; histone variant (H3.3, H2A.Z)
binding to gene promoter
Non-coding RNA (ncRNAs) epigenetic deregulations
Post-transcriptional gene expression regulation via miRNA binding with RNA-induced silencing complex (RISC) possessing
endoribonuclease activity (RNA interference), epigenetic silencing of miRNA genes (promoter hypermethylation/hypomethylation; histone
modifications); DNMT targeting
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recognized by methyl binding proteins (MBPs), including
MeCP2 (methyl CpG binding protein 2), MBD1 (methyl-
CpG binding domain protein 1) and ZBTB 33 (zinc finger
and BTB domain containing protein 33; KAISO). These
proteins form complexes with transcriptional co-repressors
(CRs), as well as HDACs and HMTs [4, 15, 23, 24]. This
indicates that these epigenetic processes—DNA methyla-
tion and histone modifications—are tightly interrelated, and
co-operate in gene expression regulation [1, 12, 15, 18, 20,
25–27]. There are evidences of direct influence of DNA
methylation on histone modifications, as well as the effect of
histone modifications on de novo DNA methylation [8, 11,
15, 28]. Still, the open question remains which of them
occurs first. The results of many research works suggest the
opposite findings [26, 28].
Additionally, very recently, it has been discovered that
not only protein-coding genes but also micro-RNAs, pos-
sessing growth inhibitory function, could be epigenetically
silenced in cancer cells [29]. According to the results of
analysis of genomic sequences of miRNA genes, approxi-
mately half of miRNAs are associated with CpG islands [30],
suggesting that the epigenetic events can influence also
miRNA expression. This is also confirmed by the findings,
that some miRNAs are upregulated when (i) the cells are
exposed to the demethylating agents, such as 5-aza-20-
deoxycytidine, (ii) when mutation of DNMT is present or
(iii) upon histone deacetylase inhibitor treatment [29, 31,
32]. Epigenetic silencing of miRNAs results in down- or up-
regulation of their targets, i.e., tumor suppressor genes or
oncogenes of known function in carcinogenesis.
Altered DNA methylation pattern in carcinogenesis
More than 20 years ago it was found that DNA methylation
patterns in cancer cells—in comparison to normal cells—
are altered [4, 23, 33]. Methylation analysis of more than
1000 non-selected CpG islands in various primary tumors
(e.g., breast, colon, testis, head and neck carcinoma) con-
firmed disturbed methylation patterns [34]. These altera-
tions involve global genome hypomethylation concerning
normally methylated sequences and/or hypermethylation of
CpG reach sequences (CpG islands) in promoters of tumor
suppressor genes (TSGs) which remain unmethylated under
normal conditions [1, 5, 6, 23, 35, 36].
DNA hypomethylation leads to carcinogenesis via three
molecular mechanisms: (1) microsatellite instability through
Fig. 1 Genetic and epigenetic changes observed in lung carcinogenesis
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activation of repetitive elements (SINE or LINE) or retro-
transposons (2) transcriptional activation and overexpres-
sion of oncogenes (3) loss of imprinting (LOI) [4, 6, 37, 38].
Global DNA hypomethylation is characteristic for neo-
plastic transformation from benign to malignant tumors
and is known to be increased with cancer progression [37,
39]. On the other hand, regional hypermethylation of TSGs
is observed in many human types of cancer, including lung,
and plays important role in carcinogenesis [1, 15, 39–46].
These processes—hypo- and hypermethylation—are often
observed in parallel in cancer cell, however they are rec-
ognized as independent epigenetic changes and are linked
with different DNA sequences [23, 35, 37].
TSGs regulate many physiological processes in cell,
such as growth, proliferation and apoptosis. They also code
for transcriptional factors, adhesion molecules, proteins
which regulate angiogenesis as well as participate in DNA
repairing system, cell cycle regulation including cyclin-
dependent kinase inhibitors and GTP-ase activators [1, 8,
26]. Epigenetic alteration of TSGs involved in regulation of
cell cycle may disturb the main cell signaling pathways
responsible for regulation of proliferation and apoptosis,
while promoter hypermethylation of DNA repair genes
prevents DNA repair process and results in accumulation of
genetic instability in transforming cell, initiating carcino-
genesis [7, 8].
Epigenetic silencing of TSGs is an early event in carci-
nogenesis. The results of many studies indicate that it is
observed also in benign tumors, as well as during early
neoplastic progression [1, 23, 36, 40, 47–56]. On the other
hand, the aberrant DNA methylation pattern significantly
correlates with poorer tumor differentiation, higher malig-
nancy and worse prognosis in a patient. It clearly indicates
that DNA methylation increases during cancer progression
[40, 47–49, 53, 54, 56].
The proposed model of CIMP (CpG island methylator
phenotype) explains cancer development through the
simultaneous inactivation of multiple genes, both TSGs
and DNA repair genes, as well as including MSI events.
The authors of the hypothesis suggested that it could be
true for many types of cancer [57]. Indeed, the recent
studies, concerning among others stomach cancer, breast
cancer and non-small cell lung carcinoma, have indicated
CIMP as independent prognostic factor [58–60].
Altered histone modifications in carcinogenesis
Nucleosomal histones are targets of a large number of post-
translational modifications, including methylation, acetyla-
tion, phosphorylation, ubiquitination, glycosylation, ADP-
ribosylation and sumoylation (see Table 1), among which
acetylation has been the most extensively investigated [61],
confirming the links to cancer initiation and progression.
This modification is dynamically preserved in vivo by the
opposing histone acetyltransferase (HAT) and deacetylase
(HDAC) actions [62].
Unstructured N-terminal tails (20–30 residues) of core
histones (H2A, H2B, H3, H4) contain multiple lysine res-
idues for covalent modifications, including acetylation.
Each core histone contains different variants and acetyla-
tion occurs on many of them. However, it has been rec-
ognized that histone acetylation does not act alone but
actively cross-talks with other histone modifications, as
well as with DNA methylation [63]. Histone acetylation
and DNA methylation are known to be intimately linked,
as mediated by a group of proteins with methyl-binding
activity (the above mentioned KAISO, MBD1 and MeCP2)
which—after binding to the methylated gene promoters—
recruit protein complexes that contain HDACs thereby
leading to gene silencing and chromatin condensation.
In normal cells, the non-disturbed histone acetylation
pattern (belonging to the above mentioned histone code)
controls many cellular and developmental processes,
including gene expression, DNA replication, DNA repair
or DNA recombination [17]. Thus, the abnormal histone
acetylation leads to cancer development via affecting many
nuclear and cellular processes [17, 64]. Moreover, disrup-
tion of enzyme activities, i.e., HAT or HDACs, may play a
significant role in uncontrolled growth and proliferation of
tumor cells. The study results have shown that treatment
with HDAC inhibitor (trichostatin A, TSA) via increasing
histone acetylation results in increased expression of many
genes encoding suppressors of invasion and metastasis,
negative cell-cycle regulators and apoptosis-related pro-
teins [65].
In addition to changes in histone acetylation, cancer
cells are also distinguished by widespread changes in his-
tone methylation patterns. The polycomb repressor com-
plex 2 (PRC2)—which is recognized as a significant
functional component for polycomb group gene family—is
involved in the initiation of silencing and contains histone
methyltransferases that can methylate histone H3 lysine
9 and 27, which are marks of silenced chromatin. The
polycomb gene BMI1, a component of PRC1, is overex-
pressed in several human cancers so that it might be
expected that aberrations in this system would give rise to
global alterations in gene silencing in cancer [66]. The
results of experimental studies indicate the increased level
of repressive polycomb mark trimethylated H3K27 in
cancer cells relative to a normal cells, resulting in histone
modification and target gene silencing [67].
The rapidly emerging data strongly indicate that the
entire epigenome is fundamentally disturbed in cancer
development. Moreover, these genome-wide changes in
the structure of the epigenome can lead to the genomic
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123
instability, that is a hallmark of cancer [68]. Accumulating
evidence clearly indicates fundamental association between
global histone modification levels and tumor aggressive-
ness, regardless of cancer type [69].
Epigenetically altered micro-RNA regulation
in carcinogenesis
Micro-RNAs are small non-coding RNAs of *22
nucleotides length. Based on the degree of homology to
their 30UTR target sequence, miRNAs can induce trans-
lational repression or degradation of target mRNAs.
Although, it has been also described that miRNAs can
also increase the expression of mRNA [70]. In human
genome, it is estimated that 1,000 miRNAs are tran-
scribed and 30 % of all genes are under miRNA regu-
lation, so one miRNA modulates hundreds of downstream
genes via post-transcriptional process. Thus, miRNAs
control a wide range of biological processes, including
cell development, proliferation and differentiation, as well
as apoptosis [71].
As miRNAs play significant roles in the normal func-
tioning of the cells, their deregulation would result in
disruption of normal cell functions and lead to diseases as
well. Indeed, in many types of human cancer the study
results indicate aberrant miRNAs expression—both over-
expression and downregulation [72, 73]. Thus, and
according to the target mRNAs, miRNAs have been pro-
posed to function as either tumor suppressors or oncogenes.
Similarly like in case of protein-coding genes associated
with cancer, the most convincing evidence linking miR-
NAs to tumorigenesis comes from genetic alterations in
cancer cells. Genetic mechanisms leading to the deletion,
amplification, or translocation of miRNAs are usually
chromosomal abnormalities. Especially, approximately
50 % of human miRNA genes are located at fragile sites or
areas of the genome which are prone to breakage and
rearrangement in cancer cells. The examples are two
tumor-suppressor microRNAs, miR-15a and miR-16-1,
that are down-regulated in 70 % of chronic lymphocytic
leukemia (CLL) cases due to chromosomal deletions or
mutations at their loci [74]. Also, factors involved in
miRNA biosynthesis machinery are dysregulated in human
tumors [75].
The results of several studies revealed that miRNAs are
also under epigenetic regulation. As mentioned earlier,
nearly half of miRNAs are associated with CpG islands,
making them prone to epigenetic modifications. It has
been proven by the findings that some miRNAs are up-
regulated upon the exposure of cells to the agent 5-aza-20-
deoxycytidine, or upon mutation of methyltransferases
(DNMTs) [29, 31]. Indeed, several miRNAs have been
identified that are silenced by CpG hypermethylation in
cancer cells, as compared to normal ones. For example,
miR-203 frequently undergoes DNA methylation in T cell
lymphoma, but not in normal T lymphocytes [76]. Hy-
permethylated miRNAs have been discovered in several
types of cancer, including breast (especially miR-9-1, but
also: mir-124a3, mir-148, mir-152, and mir-663) [31],
colorectal (miR-124a, miR-43b, miR-34c) [29, 77], oral
(miR-137, miR-193a) [78], bladder and prostate tumors
(miR-126) [79] or hepatocellular carcinoma (miR-124,
miR-203, miR-375) [80]. Epigenetic regulation of miRNA
activity is a very cell- and tumor type-specific. An
example is let-7a-3 which has been found to be hyper-
methylated in breast cancer [31], but hypomethylated in
lung cancer [81].
Additionally, in cancer cells, not only DNA methylation
status but also chromatin structure around miRNA genes
differ between cancer and normal cells, as demonstrated in
several studies. In bladder cancer Saito et al. [82] revealed,
that DNA demethylation and histone deacetylase inhibition
could reverse miR-127 expression in cancer cells. Simi-
larly, in the study performed by Bandres et al. [83], treat-
ment with a DNA methyltransferase inhibitor and a HDAC
inhibitor restored expression of 3 of the 5 microRNAs (hsa-
miR-9, hsa-miR-129 and hsa-miR-137) in colorectal cancer
cell lines.
In summary, emerging evidences suggest that epigenetic
changes of miRNA represent another mechanism that plays
a role in carcinogenesis, resulting in down- or up regulation
of the protein product of the target mRNAs. Especially,
having in mind that among miRNA target genes are
oncogenes, tumor suppressor genes, multiple cell cycle
regulators, including cyclins, cyclin-dependent kinases,
Rb-family proteins, and Cip/Kip family of cell-cycle
inhibitors, antiapoptotic genes, and key sets of genes
involved in invasion and migration, as well as those
engaged in angiogenesis [84]. The number of the identified
epigenetically altered miRNAs is still growing and their
function is being elucidated. Although, in many cases, the
prediction of specific targets remains a major bio-infor-
matic challenge and future studies will therefore have to
address the identification of target mRNAs and the eluci-
dation of the functional consequences of deregulated
miRNAs. Table 2 lists examples of miRNAs that undergo
epigenetic modifications in human cancers and their target
genes.
So far, many reports have revealed abnormal microRNA
expression in cancer cells, clearly suggesting that it is not
an exception, but the rule, in human cancer. Indeed, an
aberrant microRNA profiling (miRNome) has been
described in almost all human cancers, and could be
applied as useful marker for tumor classification, diagnosis,
and prognosis.
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Epigenetics in lung cancer
Lung cancer is the leading cause of cancer death worldwide
[85, 86]. Although lung cancer diagnoses in men decreases
each year and death rates also decline, the incidence of this
type of cancer in women increases by 0.5 % each year.
Lung cancer in women, as compared with men, occurs at a
slightly younger age, and almost half of lung cancer cases
in patients under 50 years old occurs in women, even in
those who have never smoked. The reason for this is not
completely understood. Although cigarette smoking is the
primary cause of the increased incidence of lung cancer in
women and men, some other etiologic factors, like expo-
sure to secondhand smoke, asbestos, radon or heavy metals
also plays some role [86]. Additionally some genetic fac-
tors (involving genes which participate in carcinogen
metabolism, cell growth control, DNA repair system) and
hormones such estrogen (in women) could directly or
indirectly affect cancer growth and might contribute to the
development of this type of cancer. Five year survival after
lung cancer surgery is approximately 10–70 % depending
on the stage of the tumor [87].
Primary lung cancer originates from epithelial cell. Four
basic histological types are distinguished, representing
approximately 95 % of all lung cancers. These are: Squa-
mous Cell Carcinoma/SCC/(40 %), Adenocarcinoma/AC/
(30 %) and Large Cell Cancer/LCC/(10 %) belonging to
Non-Small Cell Lung Carcinoma (NSCLC), and Small Cell
Carcinoma (SCLC). Squamous Cell Carcinomas are asso-
ciated with cigarette smoking, adenocarcinomas may be
found in patients who have never smoked.
Because of treatment concerns, lung cancers are sepa-
rated into two groups: Non- Small Cell Lung Carcinoma
(NSCLC) which accounts for approximately 80 % of all
primary lung cancers and Small Cell Lung Carcinoma
(SCLC) which accounts for 20 % [86]. NSCLCs are rela-
tively insensitive to chemotherapy and radiation therapy
compared with SCLCs. Patients with resectable lesion may
be cured by surgery or surgery followed by chemotherapy.
Local control using radiation therapy can be achieved in
a large number of patients with unresectable disease, but
cure is achieved only in a small number of patients.
SCLC differs from other histological types in terms of
many biological and clinical characteristics (high rates of
Table 2 Examples of epigenetically modified miRNAs in human cancers (excluding lung cancer) and their identified target genes
miRNA Epigenetic modification Cancer Target gene/infuence References





TrkC/overexpression [31, 83, 84,
148, 149]
miR-34a DNA hypermethylation Neuroblastoma E2F3/overexpression [150, 151]






miR-124a DNA hypermethylation Breast, colorectal, hepatocellular,
acute lymphoblastic leukemia
CDK6/oncogene derepression [29, 84, 152]
miR-126 DNA hypermethylation Bladder, prostate SPRED1, PIK3R2/derepression [153]
miR-127 DNA hypermethylation/
histone deacetylation
Bladder BCL6/oncogene derepression [82]
miR-137 DNA hypermethylation/
histone deacetylation
Colorectal oral squamous cell
carcinoma
CDK6/oncogene derepression [29, 154]
miR-193a DNA hypermethylation Oral squamous cell carcinoma E2F6/oncogene derepression [154]
miR-200 DNA hypermethylation Ovarian ZEB1, ZEB2/overexpression [155]
miR-203 DNA hypermethylation Acute lymphoblastic leukemia ABL1/overexpression [76]
miR-512-5p DNA hypermethylation/
histone deacetylation
Gastric MCL1/oncogene derepression [156]
let-7a-3 DNA hypermethylation Breast, ovarian HMGA2, KRAS, NRAS, MYC,
IGF-II/oncogene derepression
[84, 157, 158]
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase, BCL2 B-cell lymphoma 2, BCL6 B-cell lymphoma 6, BTG4 B-cell translocation gene 4,
CDK4 cyclin-dependent kinase 4, CDK6 cyclin-dependent kinase 6, E2F3-E2F transcription factor 3, E2F6-E2F transcription factor 6, HMGA2
high mobility group AT-hook 2, IGF-II insulin-like growth factor 2, KRAS-v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, NRAS
neuroblastoma RAS viral (v-ras) oncogene homolog, PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2, MCL1 myeloid cell leukemia
sequence 1, MET met proto-oncogene (hepatocyte growth factor receptor), MYC v-myc myelocytomatosis viral oncogene homolog (avian),
SPRED1-suppressor of Ras/MAPK activation, TrkC-tropomyosin-related kinase C, TSG tumor suppressor gene, ZEB1 zinc finger E-box binding
homeobox 1, ZEB2 zinc finger E-box binding homeobox 2
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proliferation, short doubling time of tumor mass, a prom-
inent tendency to early hematogenous spread, chemo- and
radiosensitivity) [86].
Epigenetic changes observed in lung carcinogenesis
include the three main aberrations: aberrant DNA methyl-
ation pattern (hyper- and hypomethylation), histone mod-
ifications and non-coding RNA regulation.
DNA hypomethylation in lung carcinogenesis
Hypomethylation in lung cancer tissue is manifested by:
(i) demethylation of the promoter regions of oncogenes; (ii)
reduced global amount of methylcytosines in the genome;
(iii) demethylation of repetitive DNA, which under phys-
iological conditions is heavily methylated; (iv) increased
transcription of the mobile elements of the genome
(transposons)—e.g., LINE sequences—and the associated
increase in mitotic recombination leading to deletions and
translocations.
Aberrant methylation pattern, mainly global hypome-
thylation of CpG regions, is a hallmark of many cancers,
including lung cancer [88]. Global demethylation generally
occurs during initiation and progression of cancerogenesis,
but in many cases it does not depend on the level of tumor
development. Additionally, the results of some studies
indicate the significance of not the total demethylation level
of the genome but rather of where the hypomethylation is
focused in the genome and what genes are affected [89].
So far only a few studies have analyzed global hypome-
thylation process in primary cancers with the aim of exploring
its clinical importance as a molecular marker [90–92].
Long interspersed element (LINE), an abundant class of
retrotransposons, occupying nearly 17 % of the human
genome, provides a surrogate marker for global hypome-
thylation [93, 94]. Hypomethylation within the promoter
region of potent LINE-1 sequence causes transcriptional
activation of LINE-1, resulting in transposition of the
retro-element and chromosomal alteration. LINE-1 meth-
ylation status may therefore be a key factor linking global
hypomethylation with genomic instability which can lead
to the progression of cancerogenesis [95–97]. The asso-
ciation between LINE-1 methylation and genomic insta-
bility also suggests that it may be a good prognostic
marker in cancer, as previous studies have reported
associations between genomic instability and the outcome
of cancer patients [97].
Regarding lung carcinoma, LINE-1 hypomethylation
was found as an independent marker of poor prognosis in
stage IA NSCLC. The results revealed that tumor LINE-1
methylation status may help to select early-stage NSCLC
patients requiring adjuvant treatment after curative surgery
[98].
Recently, Daskalos et al. [99] have examined the protein
related to the p53 tumor protein—TP73 or p73. This pro-
tein is involved in cellular stress response and develop-
ment, cell cycle regulation, and induction of apoptosis. It
possesses an intrinsic P2 promoter, controlling the
expression of the pro-apoptotic TAp73 isoform and the
anti-apoptotic DMp73 isoform. In the studied primary
NSCLC samples, the researchers demonstrated the P2 hy-
pomethylation of p73 protein and the associated over-
expression of DMp73 mRNA. They found it as a frequent
event, particularly in SCCs. Interestingly, P2 hypomethy-
lation strongly correlated with LINE-1 element hypome-
thylation, indicating that DMp73 over-expression might be
a passive consequence of global DNA hypomethylation.
In NSCLC samples the coordinated promoter demethyl-
ation of cancer/testis antigens (CTAs)—the potential, novel
candidate proto-oncogenes—associated with their upregu-
lation was also found [100]. These genes are expressed in
germline cells and in many tumors, but not in normal
somatic tissue, apart from testis and placenta. As the study
results indicate, CTA expression is tightly associated with a
squamous cell histology, and not with lung adenocarcinoma.
The coordinated regulation of CTAs and related target
genes, like MAGEA, SBSN, TKTL-1, ZNF711, G6PD, has
been found to have epigenetic background, correlated with
demethylation process. So far, SBSN, ZNF-711 and G6PD
have not been associated with tumor specific expression or
carcinogenesis.
TKTL1, encoding a transketolase-like enzyme, has been
found recently as a new and independent predictor of
survival in patients with NSCLC. Since inhibition of
transketolase enzyme activity has recently been shown to
effectively suppress tumor growth, TKTL1 may represent a
novel pharmacodiagnostic marker [101].
Another member of the cancer/testis antigen family,
BORIS (brother of the regulator of the imprinted site,
alternative symbols CTCFL; CCCTC-binding factor-like
protein) is an 11 zinc finger (ZF) protein, which is con-
sidered to be a new oncogene. BORIS presents a uniquely
paired set of genes which dysfunctions may contribute to
development of multiple tumor types via epigenetic
reprogramming at CTCF target sites, influencing many cell
proliferation-associated genes. It has been documented that
human BORIS is not only aberrantly activated in many
types of human cancers, but also maps to the cancer-
associated amplification region at 20q13 [102]. Normally,
this gene is expressed only in germ cells, but is also
aberrantly activated in numerous cancers [102, 103]. The
expression of BORIS gene is controlled predominantly by
changes in DNA-methylation, as its activation requires
promoter demethylation. In many types of human cancer,
high expression of BORIS protein correlates with the tumor
size and grade. Silencing of BORIS induces apoptosis in
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tumorous cell lines [104]. In lung carcinoma cell lines,
expression of this gene varies from high to moderate levels
[104, 105]. This, in turn, is correlated with the level of
BORIS promoter methylation [104]. Additionally, BORIS
positively regulates some of the CTAs by binding and
inducing a shift to a more open chromatin conformation
with promoter hypomethylation of MAGEA3, or indepen-
dently of promoter hypomethylation in case of MAGEA2
and MAGEA4 and thus may be a key effector involved in
their de-repression in lung cancer [106]. Additionally, in
lung cancer cells the activity of CCCTC-binding factor
(CTCF), which influences Rb2/p130 gene expression is
decreased by BORIS, therefore may correlate with pro-
gression of lung tumors [107].
The 14-3-3 proteins form a set of seven highly con-
served proteins that have recently been implicated in
human tumorigenesis. One isoform of the 14-3-3 family,
14-3-3sigma (14-3-3r), plays a crucial role in G2 check-
point by sequestering Cdc2-cyclinB1 in the cytoplasm.
Radhakrishnan et al. [108] found that the expression level
of 14-3-3r was elevated in the majority of the studied human
NSCLC tissues. The gene was hypomethylated in lung tumors
as compared with normal lung tissue. This suggests that
decreased DNA methylation results in increased expression
of 14-3-3r in NSCLC. There are findings that chemotherapy
resistance in NSCLC may also be increased with increased
expression of 14-3-3r via interaction with IGF-1. It has
been documented that IGF-1R inhibitors may increase the
efficacy of chemotherapy, particularly in SCC [109].
Another observation concerns thymosin b(10) (TMSB10).
It is a monomeric sequestering protein that regulates actin
cytoskeleton organization. TMSB10 hypomethylation, lead-
ing to its overexpression, is a quite frequent event in NSCLC,
but probably it is not a common mechanism underlying the
gene overexpression [88]. In lung cancer, overexpression of
TMSB10 was correlated with several unfavorable clinico-
pathological characteristics. What is more, thymosin b(10) is
thought to induce microvascular and lymphatic vessel for-
mation by up-regulating vascular endothelial growth factor
and vascular endothelial growth factor-C in lung cancer tis-
sues, thus promoting the distant and lymph node metastases
and being implicated in the progression of NSCLC [110].
The findings regarding hypomethylation in the above-
mentioned genes and their feasibility as diagnostic and
prognostic marker are summarized in Table 3.
DNA hypermethylation in lung carcinogenesis
As mentioned earlier, hypermethylation of gene promoters
is often associated with transcriptional silencing of tumor
suppressors. It is believed that this process leads to
the initiation and progression of carcinogenesis [111].
Numerous studies have suggested possible clinical useful-
ness of promoter hypermethylation as marker of early
diagnosis and as predictor of patient outcome in lung
cancer. There are several studies suggesting various marker
panels for lung cancer identification and differentiation.
Kwon et al. [112] have proposed six genes (CCDC37,
CYTL1, CDO1, SLIT2, LMO3, and SERPINB5) for lung
squamous cell carcinoma (SCC) identification. Especially,
methylation pattern of CYTL1 promoter region was sig-
nificantly different between early and advanced stages of
SCCs. Shames et al. [44] examined seven potential lung
cancer markers (ALDH1A3, BNC1, CCNA1, CTSZ, LOX,
MSX1 and NRCAM), three of which showed frequent
tumor-specific hypermethylation as compared with normal
tissue. In the study performed by Cortese et al. [113] four
genes (FGFR3, LAPTM5, MDK, MEOX2) were identified
as aberrantly methylated in lung cancer. MEOX2 was
uniformly higher methylated in all lung cancer samples,
while the methylation of the other three genes was cor-
related with either the differentiation status of the tumor
(MDK, LAPTM5) or with the tumor histopathological
type (FGFR3). Another panel of markers for diagnostic
application in lung cancer, elucidated recently by Begum
et al. [114], consists of six most promising genes (APC,
CDH1, MGMT, DCC, RASSF1A, and AIM1). In Chinese
population, the results of the study performed by Zhang
et al. [115] showed that nine genes (APC, CDH13,
KLK10, DLEC1, RASSF1A, EFEMP1, SFRP1, RARb
and p16(INK4A)) had a significantly higher frequency of
methylation in NSCLC as compared with normal tissues,
while several others (RUNX3, hMLH1, DAPK, BRCA1,
p14(ARF), MGMT, NORE1A, FHIT, CMTM3, LSAMP
and OPCML) showed relatively low sensitivity or speci-
ficity. Moreover, the nine genes validated in tumor tissues
also showed a significantly higher frequency of tumor-
specific hypermethylation in NSCLC plasma, as compared
with cancer-free plasma, and a 5-gene set (APC,
RASSF1A, CDH13, KLK10 and DLEC1) achieved a sen-
sitivity of 83.64 % and a specificity of 74.0 % for cancer
diagnosis.
As far as individual genes are concerned, there are
many studies which provide new information on gene-
specific hypermethylation. It has been proved that hy-
permethylation of particular genes correlates differently
with tumor’s type, stage and smoking history. However,
the methylation frequencies of the genes examined in
NSCLC samples vary according to different study results.
For example, in the study performed by Yanagawa et al.
[116] the methylation frequency was 26 % for DAPK,
34 % for FHIT, 26 % for H-cadherin, 14 % for MGMT,
8 % for p14, 27 % for p16, 38 % for RAR-beta, 42 % for
RASSF1A, 25 % for RUNX3, and 12 % for TIMP-3. Hy-
permethylation of RASSF1 and DAPK1 was found to be
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100 % specific and together identified 39 % of NSCLC
tissues. The results performed by Feng et al. [117]
revealed high levels of methylation of six genes (RASSF1,
DAPK1, BVES, CDH13, MGMT, or KCNH5) that were
100 % specific and identified 53 % of cancerous tissues.
Additionally, some other loci showing significant differ-
ences in DNA methylation levels between tumor and
non-tumor lung tissue have been identified, including:
CDKN2A EX2, CDX2, HOXA1, SFPR1, and TWIST1 gene
[118]. In another study, it has been documented that in
analyzed panel of genes (3-OST-2, RASSF1A, DcR1,
DcR2, P16, DAPK, APC, ECAD, HCAD, SOCS1, SOCS3)
only 3-OST-2 followed by RASSF1A showed the highest
level of promoter methylation in tumors as compared
to controls. Moreover, 3-OST-2 promoter hypermethyla-
tion was associated with advanced tumor stage [119].
According to the numerous studies, the most frequently
hypermethylated genes in NSCLC are listed in Table 4.
Special attention is drawn to the role of gene hyperme-
thylation in histopathological type differentiation, tumor
stage, disease outcome and prognosis.
Besides the genes listed in Table 4, the results of studies
assign several other hypermethylated genes to the partic-
ular histological types of NSCLC. For instance, CDKN2A,
CDX2, HOXA1 and OPCML are more frequently silenced
via hypermethylation in AC [118], while hypermethylated
CALCA, EVX2, GDNF, MTHFR, OPCML, TNFRSF25,
TCF21, PAX8, PTPRN2, PITX2, reveal correlation with
SSC [120, 121].
Additionally, association between gene methylation and
patient smoking history has been observed in many studies.
Although, some results are opposite. While CDKN2A,
DAPK1 and APC are found hypermethylated both in
smoking and non-smoking lung cancer patients [122–125]
others, like APC, FHIT, RASSF1A or CCND2 are strictly
correlated with smoking [117, 123, 126–128].
The list of aberrantly methylated genes in lung cancer
still expands. In future it might be useful in a more exact
prognosis of lung cancer development at early stages of the
disease.
Histone modifications in lung carcinogenesis
Dynamic histone modifications—in cooperation with the
above discussed gene promoter methylation—play critical
role in the modulation of chromatin conformation and the
regulation of gene expression.
In cancer cells, including lung cancer, hypermethylation
of promoter CpG islands of thus transcriptionally repressed
tumor suppressor genes is associated with a particular
combination of histone marks, such as deacetylation of
histones H3 and H4, loss of histone H3 lysine 4 (H3K4)
trimethylation, and gain of H3K9 and H3K27 trimethyla-
tion [1, 8, 15]. Histone H2 and H3 acetylation and trime-
thylation status in NSCLC and SCLC allows the detection
of subpopulations with differential prognosis. This suggests
that epigenetic changes associated with histone code play
important role in lung cancer tumorigenesis. Excessive
acetylation of H4K5/H4K8 and loss of trimethylation of
H4K20 was found in NSCLC and pre-invasive bronchial
dysplastic lesions. The prognostic value of epigenetic
changes involving multiple histones, in particular H2A
(H2AK5ac) and H3 (H3K4me2, H3K9ac), is greater in
Table 3 Examples of the most frequently hypomethylated genes in lung cancer and their feasibility as clinical markers
Gene Locus Clinicopathological effect, clinical marker value References




Xq28 Tight association with SCC; correlation with selective growth advantage [100, 159]
ZNF711 Xq21.1 Tight association with SCC; correlation with selective growth advantage [100]
G6PD Xq28
SBSN 19q13.13
TKTL-1 Xq28 Association with shorter patient survival; poor clinical outcome in lymph node negative NSCLCs [100, 101]
BORIS 20q13.31 Regulation of tumor growth and apoptosis, direct and/or indirect (by influencing Rb2/p130 gene
expression) correlation with tumor progression
[104, 105,
107]
14-3-3r 1p36.11 Increased expression of 14-3-3r via interaction with IGF-1, particularly in SCC; correlation with
increased chemiotherapy resistance
[108, 109]
TMSB10 2p11.2 Association with clinical stage, distant metastases, lymph node metastases, poor degree of
differentiation, short postoperative survival
[88, 110]
14-3-3r epithelial cell marker protein 1, BORIS brother of the regulator of the imprinted site, G6PD glucose-6-phosphate dehydrogenase,
MAGEA melanoma antigen family A, SBSN suprabasin, TKTL-1 transketolase-like 1, TMSB10 thymosin b 10, TP73 tumor protein p73, p73,
ZNF711 zinc finger protein 711
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early NSCLC, and the evaluation of these changes may
help in selecting early-stage NSCLC patients for adjuvant
treatment [129].
The further studies revealed that H4K20 loss of trime-
thylation identified a subpopulation of early stage (I) lung
adenocarcinoma with shorter survival time [130]. Simi-
larly, cellular levels of H3K4me2 and H3K18ac were lower
and the observed histone modification patterns were inde-
pendent predictors of clinical outcome in AC [131]. These
results strongly indicated that the lower cellular levels of
histone modifications were associated with decreased sur-
vival time. Interestingly, the levels of histone modifications
correlated positively with each other: loss of one histone
modification was generally associated with loss of other
modifications within a patient [131].
Additionally, DNA repetitive elements—that are deme-
thylated in cancer DNA—may also get demethylated and/or
deacetylated on their associated histones. The biological
effects of these alterations of histones at repetitive elements
are unclear but the researchers suggest that they probably
are associated with a more aggressive phenotype [131].
Generally, increased frequency of cancer cells with lower
global levels of histone modifications indicates poorer
clinical outcome, i.e., increased risk of tumor recurrence
and/or decreased survival time. It has been demonstrated for
several cancers, including lung cancer [69].
The mechanisms affecting histone modifications are still
being discovered, and could be attributed to improper tar-
geting, altered expression and/or activity of histone-modify-
ing enzymes because of genetic mutations, expression
changes, and/or posttranslational control [132]. The aberrant
transcription of genes that encode histone acetyltransferase
(HAT) or histone deacetylase (HDAC) enzymes or their
binding partners, has been clearly linked to carcinogenesis
[133]. The study results revealed that stronger HDAC1
expression in tumor cells was an independent predictor of a
poor prognosis in patients with adenocarcinoma of the lung
[134]. Thus, histone deacetylase inhibitors (HDACis) are now
attracting attention as promising therapeutic agents for the
treatment of cancer. The effects of HDAC inhibitors on gene
expression are highly selective, leading to transcriptional
activation of certain genes such as cyclin-dependent kinase
inhibitor p21WAF1/CIP1 and repression of others. HDAC
inhibition not only results in acetylation of histones but also
transcription factors, such as p53, GATA-1 and estrogen
receptor-alpha [135]. The results of numerous studies indicate
that inhibition of HDACs by HDACis leads to transcriptional
activation of genes involved in cancer cell growth, apoptosis,
Table 4 Examples of the most frequently hypermethylated genes in lung cancer and their feasibility as clinical markers
Gene Locus Clinicopathological effect, clinical marker value References
RASSF1A 3p21.3 Correlation with histological type (adenocarcinoma); association with tumor staging,






Correlation with NSCLC (especially with AC), and shorter survival time [114, 126, 161,
162]
FHIT 3p14.2 Association with a higher susceptibility to lung cancer development; prognostic value
in early stage of NSCLC; correlation with AC; marker of disease progression;
significant correlation with lymph node metastasis
[116, 127, 161,
163, 164]
RAR-beta 3p24 Association with advanced stage of NSCLC; correlation with shorter survival time;




MGMT 10q26 More frequently methylated in smokers and older patients; more common in SCC in
males; association with shorter survival time
[161, 167–169]
RUNX3 1p36.11 More frequently methylated in ACs; association with shorter survival time [116, 161]
CDH13 16q23.3 Correlation with AD; association with longer survival time [126, 161]









3p22.2 Correlation with advanced stage and lymph node metastasis; Association with shorter
survival time
[172, 173]
DAPK1 9q34.1 Association with early-stage NSCLC and with shorter survival time; correlation with
SCC
[174, 175]
APC adenomatous polyposis coli, CDH1 cadherin 1, CDH13 cadherin 13, H-cadherin, CDKN2A cyclin-dependent kinase inhibitor 2A,
p16(INK4), DAPK1 death-associated protein kinase 1, DLEC1 deleted in lung and esophageal cancer 1, FHIT fragile histidine triad gene, hMLH1
mutL homolog 1, colon cancer, nonpolyposis type 2, MGMT O-6-methylguanine-DNA methyltransferase, RAR-beta retinoic acid receptor beta,
RASSF1A Ras association (RalGDS/AF-6) domain family member 1, RUNX3 RUNT-related-transcription factor 3, TIMP3 tissue inhibitor or
metalloproteinase
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differentiation, migration and invasion. As demonstrated in
several studies, induced acetylation of histones H3 and H4 by
TSA in lung cancer cells led to re-expression of a number of
TSGs, including TGFBR2, SATB1, C/EBPalpha, MYO18B,
DAPK [67, 136–140]. The comprehensive study performed
by Zhong et al. [141], involving high-throughput gene
expression microarrays combined with pharmacologic inhi-
bition of DNA methylation and histone deacetylation in
NSCLC, uncovered over 200 genes upregulated by 5-azadC
and TSA treatment. Some of those genes were induced by
TSA alone (NRIP3, CYLD, CD9, ATF3, OXTR), confirming
the role of histone deacetylation in their silencing. Table 5
summarizes the examples of genes and sequences targeted by
histone modifications in lung cancer.
Epigenetic regulation of microRNA in lung
carcinogenesis
So far, deregulation of miRNA expression has been dem-
onstrated in lung cancer and its diagnostic, prognostic and
therapeutic significance has been underlined. The number
of aberrantly expressed miRNAs is still growing. Addi-
tionally, it has been observed that global decrease of
miRNA expression causally contributes to the transformed
phenotype during lung tumorigenesis [142].
As mentioned earlier, besides genetic mechanisms dis-
turbing miRNA expression, also epigenetic events can
modulate the expression and regulatory role of miRNA.
Aberrant regulation at this level was confirmed also in lung
cancer. For instance, the expression of miRNA-124a was
found to be epigenetically silenced by DNA hypermethy-
lation and, as the study results have shown, DNA meth-
yltransferase inhibitor (DNMTi) restored its expression
[29]. Conversely, micro RNA let-7a-3 is upregulated in
lung adenocarcinoma via hypomethylation. Its expression
is associated with enhanced tumor phenotypes and onco-
genic changes in transcription profiles [81].
Expression of miR-34 family—involved in lung carci-
nogenesis through p53 pathway—has also been reported to
be regulated by DNA methylation. The results of recent
analysis have revealed that promoter hypermethylation of
miR-34b/c was correlated with a high probability of
recurrence and associated with poor overall survival and
disease-free survival in stage I NSCLC [143]. This was a
relatively common event in NSCLC and might be regarded
as a potential prognostic factor for stage I NSCLC.
Regarding another micro RNA with pro-apoptotic
function and strongly downregulated in lung cancer,
namely miR-212, Incoronato et al. [144] have found that its
transcriptional inactivation in lung cancer is not associated
to DNA hypermethylation status but to a change in the
methylation status of histone tails linked to the promoter
region of this microRNA. As the study results have shown,
transcriptional silencing of miR-212 in NSCLC involved
H3K27me3/H3K9Ac or H3K9me3/H3K9Ac-associated
histone modification. Additionally, miR-212 downregula-
tion was tightly associated with the severity of the disease,
being significantly suppressed in T3/T4 staging rather than
in T1/T2 staging [144].
Another mechanism underlying the regulatory role of
micro-RNA and associated with epigenetic modifications
has been discovered in case of microRNA-449. This
miRNA belongs to the group of so called epi-miRNAs,
interacting with the members of epigenetic machinery. The
study results indicate that downexpression of miR-449a/b
might be one of mechanisms responsible for over-
expression of HDAC1 in lung cancer. MicroRNA-449a/b,
Table 5 List of genes and sequences deregulated by histone modifications in lung cancer
Histone modifications Target gene/sequence References
Histone deacetylation at target gene promoters IL-20 and its receptors (IL-20RA/B and IL-22R1) [176]
H3-Ac(-)/H3K4-Me(?/-)/DNA-Me(-) TGFBR2 [136, 137]
Loss of H3K9ac SATB1 [67]
Histone deacetylation at target gene promoters E prostanoid (EP) receptors 2–4 [177]
Loss of H3K18ac Repetitive DNA elements: D4Z4, Sat2 [131]
Loss of H3K4me2 Repetitive DNA elements: D4Z4, NBL2 [131]
H3 deacetylation at target gene promoter VILIP-1 [178]
Histone deacetylation at target gene promoters NRIP3, CYLD, CD9, ATF3, OXTR [141]
H3 and H4 deacetylation at target gene promoter C/EBPalpha [138]
H3 and H4 deacetylation at target gene promoter MYO18B [139]
Histone deacetylation at target gene promoter DAPK [140]
ATF3 activating transcription factor 3, CD9 CD9 antigen, C/EBPalpha tumor suppressor CCAAT/enhancer-binding protein-alpha, CYLD
cylindromatosis, DAPK death-associated protein kinase, IL-20 interleukin 20, MYO18B myosin XVIIIB, NRIP3 nuclear receptor interacting
protein 3, OXTR oxytocin receptor, SATB1 special AT-rich binding protein 1, TGFBR2 transforming growth factor, beta receptor II, VILIP-1
visinin-like protein-1
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possessing tumor suppressor function, inhibits cell growth
and anchorage-independent growth. It has been shown, that
co-treatment with miR-449a and HDAC inhibitors leads to
significant tumor growth reduction as compared with
HDAC inhibitor mono-treatment. These results suggest
that miR-449a/b might be a potential therapeutic candidate
in patients with primary lung cancer [145]. Another epi-
miRNAs belong to miR-29 family (29a, 29b, and 29c),
which target the de novo DNA methyltransferases DNMT-
3A and 3B. In lung cancer miR-29s expression has been
found to be inversely correlated with both enzymes [146].
According to the study results, the enforced expression of
miR-29s in lung cancer cell lines results in a global
reduction of DNA methylation, thus leading to re-expres-
sion of methylation-silenced tumor suppressor genes
(FHIT, WWOX) and, additionally, inhibits tumorigenicity
in vitro and in vivo.
The study findings support a role of epi-miRNAs in
epigenetic normalization of NSCLC. They could be a basis
for the development of miRNA-based strategies for the
treatment of lung cancer (Table 5).
The findings on miRNA regulation via epigenetic
mechanisms in lung cancer are listed in Table 6.
Conclusions
In the past decade epigenetics has been one of the most
promising and rapidly expanding research fields. Since the
discovery of altered DNA methylation patterns, i.e., global
DNA hypomethylation and tumor suppressor promoter
hypermethylation in cancer cells, in 1980s–1990s, a variety
of other epigenetic changes have been identified. They
include a wide spectrum of histone modifications and the
role of non-coding RNAs. Nowadays a huge amount of
knowledge confirms that the epigenetic setting is com-
pletely disturbed in human cancer. Epigenetic processes
play a key role in the onset and progression of numerous
types of tumors.
In lung cancer promoter DNA hypermethylation,
identified for still growing number of TSGs, and single
gene hypomethylation, are recognized as belonging to
the earliest events in lung carcinogenesis and increasing
with the disease progression. Cancer-specific hyperme-
thylation and hypomethylation events can be recognized
in lung tissue biopsies, but also in biological fluids, like
sputum, allowing to predict lung cancer incidence using
non-invasive methods. Specific epigenetic biomarkers,
associated with hyper- or hypomethylation, can distin-
guish NSCLC subtypes or reveal early stages of lung
tumorigenesis affecting smokers. Aberrant methylation
of certain genes is associated with poor outcome and
can be useful for the establishment of lung tumor
prognosis.
In the recent years, histone-based and miRNA-based
epigenetic signatures have also been incorporated into the
molecular search for biomarkers in cancer. Specific histone
code can support the selection of early stage disease
patients and predict their clinical outcome. Additionally,
the role of miRNAs, the very recently discovered level of
epigenetic control, is gaining importance. The aberrant
expression of several miRNAs has been associated with
differential diagnosis of NSCLC as well as with survival
and cancer recurrence in lung cancer patients.
As potentially reversible, epigenetic aberrations are the
targets for potential treatment strategies in cancer therapy.
The growing number of reports outline the usefulness of
the epigenetic events for lung cancer diagnostic, prognostic
and targeted epigenetic therapy.
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